D
Zymeworks Inc.
ZYME
$12.25
-$0.30-2.39%
D
Sell
11/4/2024Downgrade
Zymeworks Inc. (ZYME) was downgraded to D- from D on 11/4/2024 due to a decline in the efficiency index, growth index and solvency index. The quick ratio declined from 6.62 to 3.82, EBIT declined 33.62% from -$25.6M to -$34.21M, and total revenue declined 16.85% from $19.24M to $16M.
Zymeworks Inc. (ZYME) was downgraded to D- from D on 11/4/2024 due to a decline in the efficiency index, growth index and solvency index. The quick ratio declined from 6.62 to 3.82, EBIT declined 33.62% from -$25.6M to -$34.21M, and total revenue declined 16.85% from $19.24M to $16M.
D
Sell
3/8/2024Downgrade
Zymeworks Inc. (ZYME) was downgraded to D from C on 3/8/2024 due to a significant decline in the valuation index, efficiency index and growth index.
Zymeworks Inc. (ZYME) was downgraded to D from C on 3/8/2024 due to a significant decline in the valuation index, efficiency index and growth index.
C
Hold
1/12/2024Upgraded
Zymeworks Inc. (ZYME) was upgraded to C from C- on 1/12/2024 due to an increase in the total return index and volatility index.
Zymeworks Inc. (ZYME) was upgraded to C from C- on 1/12/2024 due to an increase in the total return index and volatility index.
C
Hold
11/8/2023Upgraded
Zymeworks Inc. (ZYME) was upgraded to C- from D on 11/8/2023 due to a significant increase in the growth index, efficiency index and valuation index. Total revenue increased 135.73% from $7M to $16.51M, earnings per share increased from -$0.761 to -$0.41, and net income increased 43.92% from -$51.15M to -$28.69M.
Zymeworks Inc. (ZYME) was upgraded to C- from D on 11/8/2023 due to a significant increase in the growth index, efficiency index and valuation index. Total revenue increased 135.73% from $7M to $16.51M, earnings per share increased from -$0.761 to -$0.41, and net income increased 43.92% from -$51.15M to -$28.69M.
D
Sell
5/15/2023Downgrade
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 5/15/2023 due to a significant decline in the growth index, solvency index and efficiency index. Operating cash flow declined 125.41% from $327.36M to -$83.19M, EBIT declined 108.39% from $319.37M to -$26.79M, and earnings per share declined from $4.6483 to -$0.3702.
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 5/15/2023 due to a significant decline in the growth index, solvency index and efficiency index. Operating cash flow declined 125.41% from $327.36M to -$83.19M, EBIT declined 108.39% from $319.37M to -$26.79M, and earnings per share declined from $4.6483 to -$0.3702.
D
Sell
3/8/2023Upgraded
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 3/8/2023 due to a significant increase in the valuation index, growth index and efficiency index. Total revenue increased 15,198.1% from $2.63M to $402.49M, net income increased 746.72% from -$47.85M to $309.43M, and earnings per share increased from -$0.72 to $4.6483.
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 3/8/2023 due to a significant increase in the valuation index, growth index and efficiency index. Total revenue increased 15,198.1% from $2.63M to $402.49M, net income increased 746.72% from -$47.85M to $309.43M, and earnings per share increased from -$0.72 to $4.6483.
D
Sell
2/9/2023Upgraded
Zymeworks Inc. (ZYME) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index and valuation index.
Zymeworks Inc. (ZYME) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index and valuation index.
E
Sell
2/8/2023Downgrade
Zymeworks Inc. (ZYME) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index, valuation index and volatility index. Debt to equity increased from 0.01 to 0.03, and the quick ratio declined from 3.07 to 3.
Zymeworks Inc. (ZYME) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index, valuation index and volatility index. Debt to equity increased from 0.01 to 0.03, and the quick ratio declined from 3.07 to 3.
D
Sell
10/17/2022Upgraded
Zymeworks Inc. (ZYME) was upgraded to D from D- on 10/17/2022 due to an increase in the volatility index and total return index.
Zymeworks Inc. (ZYME) was upgraded to D from D- on 10/17/2022 due to an increase in the volatility index and total return index.
D
Sell
9/30/2022Downgrade
Zymeworks Inc. (ZYME) was downgraded to D- from D on 9/30/2022 due to a decline in the volatility index.
Zymeworks Inc. (ZYME) was downgraded to D- from D on 9/30/2022 due to a decline in the volatility index.
D
Sell
9/9/2022Upgraded
Zymeworks Inc. (ZYME) was upgraded to D from D- on 9/9/2022 due to an increase in the volatility index and valuation index.
Zymeworks Inc. (ZYME) was upgraded to D from D- on 9/9/2022 due to an increase in the volatility index and valuation index.
D
Sell
8/23/2022Downgrade
Zymeworks Inc. (ZYME) was downgraded to D- from D on 8/23/2022 due to a decline in the volatility index and valuation index.
Zymeworks Inc. (ZYME) was downgraded to D- from D on 8/23/2022 due to a decline in the volatility index and valuation index.
D
Sell
8/8/2022Upgraded
Zymeworks Inc. (ZYME) was upgraded to D from E+ on 8/8/2022 due to an increase in the growth index and solvency index. Total revenue increased 184.03% from $1.92M to $5.44M, earnings per share increased from -$1.1882 to -$0.9739, and EBIT increased 10.52% from -$73.56M to -$65.82M.
Zymeworks Inc. (ZYME) was upgraded to D from E+ on 8/8/2022 due to an increase in the growth index and solvency index. Total revenue increased 184.03% from $1.92M to $5.44M, earnings per share increased from -$1.1882 to -$0.9739, and EBIT increased 10.52% from -$73.56M to -$65.82M.
E
Sell
4/20/2022Downgrade
Zymeworks Inc. (ZYME) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and growth index.
Zymeworks Inc. (ZYME) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and growth index.
D
Sell
3/28/2022Downgrade
Zymeworks Inc. (ZYME) was downgraded to D- from D on 3/28/2022 due to a large decline in the total return index, volatility index and growth index.
Zymeworks Inc. (ZYME) was downgraded to D- from D on 3/28/2022 due to a large decline in the total return index, volatility index and growth index.
D
Sell
11/29/2021Downgrade
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 11/29/2021 due to a decline in the total return index and volatility index.
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 11/29/2021 due to a decline in the total return index and volatility index.
D
Sell
11/12/2021Upgraded
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 11/12/2021 due to an increase in the valuation index.
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 11/12/2021 due to an increase in the valuation index.
D
Sell
11/9/2021Upgraded
Zymeworks Inc. (ZYME) was upgraded to D from D- on 11/9/2021 due to a major increase in the growth index. Total revenue increased 148.16% from $1.77M to $4.4M, EBIT increased 11.5% from -$68.89M to -$60.96M, and earnings per share increased from -$1.3131 to -$1.2465.
Zymeworks Inc. (ZYME) was upgraded to D from D- on 11/9/2021 due to a major increase in the growth index. Total revenue increased 148.16% from $1.77M to $4.4M, EBIT increased 11.5% from -$68.89M to -$60.96M, and earnings per share increased from -$1.3131 to -$1.2465.
D
Sell
11/8/2021Downgrade
Zymeworks Inc. (ZYME) was downgraded to D- from D on 11/8/2021 due to a large decline in the solvency index, growth index and total return index. EBIT declined 53.38% from -$44.87M to -$68.82M, earnings per share declined from -$0.8681 to -$1.3131, and the quick ratio declined from 5.92 to 4.45.
Zymeworks Inc. (ZYME) was downgraded to D- from D on 11/8/2021 due to a large decline in the solvency index, growth index and total return index. EBIT declined 53.38% from -$44.87M to -$68.82M, earnings per share declined from -$0.8681 to -$1.3131, and the quick ratio declined from 5.92 to 4.45.
D
Sell
5/7/2021Downgrade
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 5/7/2021 due to a substantial decline in the growth index, total return index and solvency index. Total revenue declined 95.89% from $15.68M to $644, EBIT declined 19.86% from -$37.49M to -$44.94M, and earnings per share declined from -$0.741 to -$0.87.
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 5/7/2021 due to a substantial decline in the growth index, total return index and solvency index. Total revenue declined 95.89% from $15.68M to $644, EBIT declined 19.86% from -$37.49M to -$44.94M, and earnings per share declined from -$0.741 to -$0.87.
D
Sell
3/4/2021Upgraded
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 3/4/2021 due to a significant increase in the growth index, solvency index and volatility index. Total revenue increased 493.27% from $2.64M to $15.68M, EBIT increased 49.1% from -$73.74M to -$37.53M, and earnings per share increased from -$1.4255 to -$0.7409.
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 3/4/2021 due to a significant increase in the growth index, solvency index and volatility index. Total revenue increased 493.27% from $2.64M to $15.68M, EBIT increased 49.1% from -$73.74M to -$37.53M, and earnings per share increased from -$1.4255 to -$0.7409.
D
Sell
11/5/2020Downgrade
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 11/5/2020 due to a large decline in the growth index and valuation index. Earnings per share declined from -$0.7671 to -$1.43, EBIT declined 82.65% from -$40.35M to -$73.69M, and total revenue declined 78.61% from $12.36M to $2.64M.
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 11/5/2020 due to a large decline in the growth index and valuation index. Earnings per share declined from -$0.7671 to -$1.43, EBIT declined 82.65% from -$40.35M to -$73.69M, and total revenue declined 78.61% from $12.36M to $2.64M.
D
Sell
5/8/2020Upgraded
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 5/8/2020 due to a noticeable increase in the growth index and valuation index. Total revenue increased 340.54% from $1.88M to $8.27M, earnings per share increased from -$1.6573 to -$0.64, and EBIT increased 51.4% from -$73.83M to -$35.88M.
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 5/8/2020 due to a noticeable increase in the growth index and valuation index. Total revenue increased 340.54% from $1.88M to $8.27M, earnings per share increased from -$1.6573 to -$0.64, and EBIT increased 51.4% from -$73.83M to -$35.88M.
D
Sell
3/4/2020Downgrade
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 3/4/2020 due to a noticeable decline in the efficiency index, valuation index and growth index. Operating cash flow declined 234.14% from -$10.88M to -$36.35M, net income declined 137.06% from -$30.48M to -$72.24M, and earnings per share declined from -$0.7015 to -$1.655.
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 3/4/2020 due to a noticeable decline in the efficiency index, valuation index and growth index. Operating cash flow declined 234.14% from -$10.88M to -$36.35M, net income declined 137.06% from -$30.48M to -$72.24M, and earnings per share declined from -$0.7015 to -$1.655.
D
Sell
8/2/2019Upgraded
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 8/2/2019 due to a noticeable increase in the total return index, efficiency index and volatility index. Total capital increased 91.92% from $178.12M to $341.85M.
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 8/2/2019 due to a noticeable increase in the total return index, efficiency index and volatility index. Total capital increased 91.92% from $178.12M to $341.85M.
D
Sell
5/7/2019Downgrade
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 5/7/2019 due to a large decline in the growth index, solvency index and efficiency index. EBIT declined 270.47% from $8.54M to -$14.55M, earnings per share declined from $0.287 to -$0.43, and net income declined 247.1% from $9.27M to -$13.64M.
Zymeworks Inc. (ZYME) was downgraded to D from D+ on 5/7/2019 due to a large decline in the growth index, solvency index and efficiency index. EBIT declined 270.47% from $8.54M to -$14.55M, earnings per share declined from $0.287 to -$0.43, and net income declined 247.1% from $9.27M to -$13.64M.
D
Sell
2/1/2019Upgraded
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 2/1/2019 due to a large increase in the total return index and volatility index.
Zymeworks Inc. (ZYME) was upgraded to D+ from D on 2/1/2019 due to a large increase in the total return index and volatility index.
D
Sell
5/1/2018Upgraded
Zymeworks Inc. (ZYME) was upgraded to D from D- on 5/1/2018 due to a significant increase in the growth index, solvency index and efficiency index. Total revenue increased 41,976.47% from $119 to $50.07M, operating cash flow increased 421.06% from -$12.15M to $39.02M, and net income increased 301.5% from -$16.25M to $32.73M.
Zymeworks Inc. (ZYME) was upgraded to D from D- on 5/1/2018 due to a significant increase in the growth index, solvency index and efficiency index. Total revenue increased 41,976.47% from $119 to $50.07M, operating cash flow increased 421.06% from -$12.15M to $39.02M, and net income increased 301.5% from -$16.25M to $32.73M.
D
Sell
1/2/2018Upgraded
Zymeworks Inc. (ZYME) was upgraded to D- from E on 1/2/2018 due to an increase in the total return index, efficiency index and volatility index.
Zymeworks Inc. (ZYME) was upgraded to D- from E on 1/2/2018 due to an increase in the total return index, efficiency index and volatility index.
E
Sell
10/2/2017Upgraded
Zymeworks Inc. (ZYME) was upgraded to E from E- on 10/2/2017 due to a significant increase in the solvency index and valuation index. The quick ratio increased from 1.41 to 5.22.
Zymeworks Inc. (ZYME) was upgraded to E from E- on 10/2/2017 due to a significant increase in the solvency index and valuation index. The quick ratio increased from 1.41 to 5.22.
E
Sell
7/24/2017None
Zymeworks Inc. (ZYME) was downgraded to E- from U on 07/24/2017.
Zymeworks Inc. (ZYME) was downgraded to E- from U on 07/24/2017.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
